A new case study suggests that a personalized exercise program could improve the quality of life for people fighting malignant mesothelioma. An estimated 2,500 Americans receive a mesothelioma diagnosis every year. Most of them are over 65. This population is typically less active than younger people anyway. It can be even harder to get enough physical activity when they are depleted by cancer and treatment. Research shows that physical activity does more than make patients stronger. It can also help them fight cancers like malignant mesothelioma. But many patients still do not get enough. The new report shows how a custom exercise program can help mesothelioma patients feel and function better. Physical Activity and Mesothelioma Treatment Pleural mesothelioma is a … Continue reading Personalized Exercise Program Improves Mesothelioma Quality of Life
Researchers at a top US cancer center are experimenting with a new approach to immunotherapy for pleural mesothelioma – with exciting results. The research was done at Memorial Sloan Kettering Cancer Center in New York and published in a recent issue of Cancer Discovery. The Phase I trial is the first to treat pleural mesothelioma patients with CAR-T cell therapy and the PD-1 blocker pembrolizumab (Keytruda). Although the trial was small, 83 percent of patients lived for more than a year. Some lived for nearly two. Malignant Mesothelioma commonly claims the lives of patients within months. This new type of immunotherapy for pleural mesothelioma could be a breakthrough in improving survival. The Challenge of Malignant Mesothelioma Scientists have known about … Continue reading CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma?
A new study on the link between drinking and cancer risk may make people at risk for mesothelioma think twice about their alcohol consumption. The new study is the latest to draw a direct line between drinking and cancer risk. According to the report released this week, more than 4 percent of new cancer cases last year were linked to alcohol use. Asbestos exposure is the main cause of mesothelioma. But not everyone who is exposed to asbestos gets mesothelioma. Genetic factors play a role. But the new alcohol study suggests that drinking could also be a catalyst for cancer development. The Link Between Drinking and Cancer Risk The new study was conducted by scientists from the International Agency for … Continue reading Mesothelioma Update: Drinking and Cancer Risk
A new predictive model may make it easier for cancer doctors to choose the best mesothelioma surgery for each pleural mesothelioma patient. There are two major surgical approaches for pleural mesothelioma. One involves removal of a lung and the other does not. Right now, the choice about which surgery to have is based on patient demographics, symptoms, and lab values. Which surgery is most common at the institution may also play a role. Many surgeons have strong opinions about which is the best mesothelioma surgery. But Harvard researchers say the new predictive model they tested is a better way to stratify mesothelioma patients. Their study suggests that this approach may lead to better treatment outcomes and more accurate clinical trials. … Continue reading New Test May Help Doctors Choose the Best Mesothelioma Surgery
The latest report on cancer death rates in the US is both good and bad news for people with malignant mesothelioma. The good news is that the rate of death from all types of cancer has declined in recent years. This is true for both men and women of all races. Better drugs and improved screening tools are some of the reasons. The bad news for people with mesothelioma is that the likelihood of dying from it is not declining as rapidly as overall cancer death rates. Asbestos cancer continues to confound cancer researchers around the world. Mesothelioma: A Rare Cancer with High Mortality Malignant mesothelioma is one of the rarest cancers in the US. That is fortunate because the … Continue reading Annual Report on Cancer Death Rates: Good and Bad News for Mesothelioma Patients
A new study suggests that treatment with vinorelbine may boost progression free survival for people with relapsed malignant mesothelioma. Mesothelioma is a virulent cancer caused by exposure to asbestos. Chemotherapy is the primary first-line treatment. But this cancer almost always comes back within a few months. Now, researchers at the UK’s University of Leicester say treatment with vinorelbine might keep mesothelioma at bay for several months longer. They presented their research at this months’ annual meeting of the American Society of Clinical Oncology. Second-Line Mesothelioma Treatments Needed Pleural mesothelioma is the most common form of mesothelioma. Tumors grow on the membrane around the lungs. The symptoms often mimic lung cancer but can be even more deadly. Some of the healthiest … Continue reading Treatment with Vinorelbine for Relapsed Pleural Mesothelioma
A recent study found no link between mesothelioma survival and exposure to pleural fluid. But that does not necessarily mean the link doesn’t exist. Pleural fluid is also called pleural effusions or “water on the lungs”. It is extra fluid that builds up around the lungs. It is common in people with heart failure, kidney or liver disease, pleural mesothelioma and some other kinds of cancer. Pleural effusions are usually treated as an uncomfortable mesothelioma symptom. Draining the fluid can help patients breathe easier. But researchers at Oxford University wondered whether the pleural fluid itself could shorten mesothelioma survival. In this study, the answer appears to be no. But the researchers warn this may not be the final word on … Continue reading Does Pleural Fluid Exposure Affect Mesothelioma Survival?
The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102. Norweigian drug maker Targovax recently released the final survival data from a two-year study of ONCOS-102 in people with malignant pleural mesothelioma. Eighteen months into the study, it looked like some of the patients on the immunotherapy treatment would live longer than two years. Now that the ONCOS-102 study has passed the two year mark, researchers say median survival may be even longer. Average survival is a year or less on standard mesothelioma therapies. This makes the news about ONCOS-102 especially exciting. Standard of Care Versus Immunotherapy Treatment Malignant mesothelioma is an aggressive malignancy with a poor prognosis. Even patients in overall good health face a grim outlook. … Continue reading Immunotherapy Treatment ONCOS-102: News Keeps Getting Better
New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to respond to immunotherapy. Immunotherapy is one of the most promising new approaches to malignant mesothelioma. But not every patient responds. A new Dutch study suggests that biomarkers in a patient’s exhaled breath may be indicators of immunotherapy response. The eNose breath test can identify those biomarkers quickly and easily. The technology might make it easier to decide on the best mesothelioma treatment. Immunotherapy for Malignant Mesothelioma Pleural mesothelioma is a rare but deadly cancer of the lung lining. Until last year, chemotherapy with Alimta (pemetrexed) was the only FDA-approved systemic treatment. In 2020, the FDA approved a combination of immunotherapy … Continue reading Breath Test Could Predict Mesothelioma Immunotherapy Response
Three small studies suggest that dendritic cells may offer a new, more promising way to fight malignant pleural mesothelioma. Dendritic cells are immune system cells that function as messengers. They are supposed to signal T-cells to attack cancers like malignant mesothelioma. But mesothelioma cells can keep dendritic cells from doing their job. The result is that the number of activated T-cells around mesothelioma tumors stays low and the tumors keep growing. Now, Dutch researchers studying the problem say a vaccine made from dendritic cells may hold the answer. They analyzed the results of three small dendritic cell studies. These studies included a total of 29 mesothelioma patients. Some of the patients in these studies lived much longer than mesothelioma patients normally … Continue reading Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies